



(51) International Patent Classification:

A61K 31/485 (2006.01) A61K 31/194 (2006.01)
A61K 31/765 (2006.01) A61K 33/42 (2006.01)
A61P 25/04 (2006.01)

(21) International Application Number:

PCT/SE2011/051161

(22) International Filing Date:

29 September 2011 (29.09.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/388,501 30 September 2010 (30.09.2010) US

(71) Applicants (for all designated States except US):

ASTRAZENECA AB [SE/SE]; SE-151 85 Södertälje (SE).
NEKTAR THERAPEUTICS [US/US]; 455 Mission
Bay Boulevard South, San Francisco, California 94158
(US).

(72) Inventors; and

(75) Inventors/Applicants (for US only):

ÅSLUND, Bengt Leonard [SE/SE]; AstraZeneca R&D Södertälje, SE-151
85 Södertälje (SE). **AURELL, Carl-Johan** [SE/SE]; As-
traZeneca R&D Södertälje, SE-151 85 Södertälje (SE).
BOHLIN, Martin Hans [SE/SE]; AstraZeneca R&D
Södertälje, SE-151 85 Södertälje (SE). **SEBHATU, Tes-
fai** [SE/SE]; AstraZeneca R&D Södertälje, SE-151 85
Södertälje (SE). **YMÉN, Bo Ingvar** [SE/SE]; As-
traZeneca R&D Södertälje, SE-151 85 Södertälje (SE).
HEALY, Eric Thomas [US/US]; Nektar Therapeutics,
455 Mission Bay Boulevard South, Suite 100, San Fran-

cisco, California 94158 (US). **JENSEN, David Richard**
[US/US]; Nektar Therapeutics, 455 Mission Bay Boule-
vard South, Suite 100, San Francisco, California 94158
(US). **JONAITIS, David Thomas** [US/US]; SSCI, A Di-
vision of APTUIT, 3065 Kent Avenue, West Lafayette,
Indiana 47906-1076 (US). **PARENT, Stephan** [US/US];
SSCI, A Division of APTUIT, 3065 Kent Avenue, West
Lafayette, Indiana 47906-1076 (US).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROP-**

ERTY; AstraZeneca AB, SE-151 85 Södertälje (SE).

(81) Designated States (unless otherwise indicated, for every


kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT,
LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS,
SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: CRYSTALLINE NALOXOL-PEG CONJUGATE



(57) Abstract: Naloxol-polyethylene glycol conjugates of the formula: are provided in oxalate or phosphate salt forms including crystalline forms. Methods of preparing the salt forms and pharmaceutical compositions comprising the salt forms are also provided.



Published:

— *with international search report (Art. 21(3))*